Poly(I:C) used for human dendritic cell maturation preserved their ability to secondarily secrete bioactive IL-12

International Immunology

Volumn 16, Issue 5, 2004, Pages 767-773

  Rouas, Redouane ^a   Lewalle, Philippe ^a   El Ouriaghli, Frank ^a   Nowak, Berengere ^a   Duvillier, Hughes ^a   Martiat, Philippe ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

CD40 ligand; IL 12; Immunotherapy; Mature dendritic cell

Indexed keywords

CD40 LIGAND; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVITY; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; REPRODUCIBILITY; TARGET CELL;

ANTIGENS, SURFACE; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; POLY I-C; PROTEIN SUBUNITS;

EID: 2442509079     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/dxh077     Document Type: Article

References (54)

1. Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271.
2. Hart, D. N. J. 1997. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90:3245.
3. Banchereau, J. and Steinman, R. M. 1998. Dendritic cells and the control of immunity. Nature 392:245.
4. h2 phenotype by dendritic cells. J. Immunol. 165:1877.
5. Celluzzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T. and Falo, L. D. Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:283.
6. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. and Schadendorf, D. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
7. Salgaller, M. L., Lodge, P. A., McLean, J. G., Tjoa, B. A., Loftus, D. J., Ragde, H., Kenny, G. M., Rogers, M., Boynton, A. L. and Murphy, G. P. 1998. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 35:144.
8. + T-cell in humans without foreign helper epitopes. J. Clin. Invest. 105:R9.
9. Dhodapkar, M. V. and Bhardwaj, N. 2000. Active immunization of humans with dendritic cells. J. Clin. Immunol. 20:167.
10. Osada, T., Fujimaki, T., Takamizawa, M., Tsuno, N. H., Kirino, T. and Shibata, Y. 2001. Dendritic cells activate antitumor immunity for malignant intracranial germ cell tumor: a case report. Jpn. J. Clin. Oncol. 31:403.
11. + progenitor-derived dendritic cell vaccine. Cancer Res. 61:6451.
12. + melanoma patients by mature monocyte-derived dendritic cells. J. Immunol. 165:3492.
13. Medzhitov, R. and Janeway, C., Jr. 2000. Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173:89.
14. h1 phenotype. Blood 90:1920.
15. Trinchieri, G. 1998. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70:83.
16. Grufman, P. and Karre, K. 2000. Innate and adaptive immunity to tumors: IL-12 is required for optimal responses. Eur. J. Immunol. 30:1088.
17. Gherardi, M. M., Ramirez, J. C. and Esteban, M. 2001. Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens. Histol. Histopathol. 16:655.
18. Grohmann, U., Bianchi, R., Ayroldi, E., Belladonna, M. L., Surace, D., Fioretti, M. C. and Puccetti, P. 1997. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J. Immunol. 158:3593.
19. h2 development. Nat. Immunol. 1:199.
20. Dhodapkar, M. V., Steinman, R. M., Sapp, M., Desai, H., Fossella, C., Krasovsky, J., Donahoe, S. M., Dunbar, P. R., Cerundolo, V., Nixon, D. F. and Bhardwaj, N. 1999. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104:173.
21. Thurner, B., Haendle, I., Roder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., Brocker, E. B., Steinman, R. M., Enk, A., Kampgen, E. and Schuler, G. 1999. Vaccination with MACE-3A1 peptide-pulsed mature, monocytes-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669.
22. Jonuleit, H., Giesecke-Tuettenberg, A., Tuting, T., Thurner-Schuler, B., Stuge, T. B., Paragnik, L., Kandemir, A., Lee, P. P., Schuler, G., Knop, J. and Enk, A. H. 2001. A comparison of two types of dendritic cells as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer 93:243.
23. Morse, M. A., Mosca, P. J., Clay, T. M. and Lyerly, H. K. 2002. Dendritic cell maturation in active immunotherapy strategies. Expert Opin. Biol. Ther. 2:35.
24. Shuler-Thurner, B., Schultz, E. S., Berger, T. G., Weinlich, G., Ebner, S., Woerl, P., Bender, A., Feuerstein, B., Fritsch, P. O., Romani, N. and Shuler, G. 2002. Rapid induction of tumor-specific type 1 helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocytes-derived dendritic cells. J. Exp. Med. 195:1279.
25. Sallusto, F. and Lanzavecchia, A. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109.
26. Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A. and Alber, G. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747.
27. Romani, N., Reider, D., Heuer, M., Ebner, S., Kampgen, E., Eibl, B., Niederwieser, D. and Schuler, G. 1996. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 196:137.
28. Cella, M., Sallusto, F. and Lanzavecchia, A. 1997. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9:10.
29. Snijders, A., Kalinski, P., Hilkens, C. M. and Kapsenberg, M. L. 1998. High-level IL-12 production by human dendritic cells requires two signals. Int. Immunol. 10:1593.
30. Cella, M., Salio, M., Sakakibara, Y., Langen, H., Julkunen, I. and Lanzavecchia, A. 1999. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med. 189:821.
31. Verdijk, R. M., Mutis, T., Esendam, B., Kamp, J., Melief, C. J., Brand, A. and Goulmy, E. 1999. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J. Immunol. 163:57.
32. Jonuleit, H., Kühn, U., Müller, G., Steinbrink, K., Paragnik, L., Schmidt, E., Knop, J. and Enk, A. H. 1997. Proinflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27:3135.
33. Kalinski, P., Hilkens, C. M., Wierenga, E. A. and Kapsenberg, M. L. 1999. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signals. Immunol. Today 20:561.
34. h1-inducing capacity in myeloid dendritic cells requires environmental instruction. J. Immunol. 164:4507.
35. h cell-polarizing signals. J. Immunol. 168:1704.
36. Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., Van Kooten, C., Durand, I. and Banchereau, J. 1994. Activation of human dendritic cells through CD40L cross linking. J. Exp. Med. 180:1263.
37. 2, promote type 2 cytokine production in maturing human naive T helper cells. J. Immunol. 159:28.
38. Bender, A., Sapp, M., Schuler, G., Steinman, R. M. and Bhardwaj, N. 1996. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 196:121.
39. Steinbrink, K., Wölfl, M., Jonuleit, H., Knop, J. and Enk, A. H. 1997. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159:4772.
40. + T cells resulting in a failure to lyse tumor cells. Blood 93:1634.
41. + dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J. Immunol. 161:2804.
42. Gabrilovitch, D. I., Chen, H. L., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D. and Carbone, D. P. 1996. Production of vascular endothelium growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2:1096.
43. + regulatory T cells in vivo in humans. Blood 100:174.
44. Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C. and Bhardwaj, N. 2001. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193:233.
45. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192:1213.
46. 2 is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 97:3466.
47. Muzio, M., Bosisio, D., Polentarutti, N., D'amico, G., Stoppacciaro, A., Mancinelli, R., van't Veer, C., Penton-Rol, G., Ruco, L. P., Allavena, P. and Mantovani, A. 2000. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol. 164:5998.
48. Robinson, R. A., DeVita, V. T., Levy, H. B., Baron, S., Hubbard, S. P. and Levine, A. S. 1976. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patients with leukemia or solid tumors. J. Natl Cancer Inst. 57:599.
49. Salazar, A. M., Levy, H. B., Ondra, S., Kende, M., Scherokman, B., Brown, D., Mena, H., Martin, N., Schwab, K., Donovan, D., Dougherty, D., Pulliam, M., Ippolito, M., Graves, M., Brown, H. and Ommaya, A. 1996. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl-cellulose: an open pilot study. Neurosurgery 38:1096.
50. Strayer, D. R., Carter, W. A., Brodsky, I., Cheney, P., Peterson, D., Salvato, P., Thompson, C., Loveless, M., Shapiro, D. E., Elsasser, W., et al. 1994. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin. Infect. Dis. 18(Suppl. 1):S88.
51. Carter, W. A., Strayer, D. R., Brodsky, I., Lewin, M., Pellegrino, M. G., Einck, L., Henriques, H. F., Simon, G. L., Parenti, D. M., Scheib, R. G., et al. 1987. Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Lancet i:1286.
52. Gillespie, D., Hubbell, H. R., Carter, W. A., Midgette, P., Elsasser, W., Mullaney, R. and Strayer, D. R. 1994. Synergistic inhibition of AZT-resistant HIV by AZT combined with poly(I):poly(C12U) without synergistic toxicity to bone marrow progenitor cell elements. In Vivo 8:375.
53. Spisek, R., Bretaudeau, L., Barbieux, I., Meflah, K. and Gregoire, M. 2001. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol. Immunother. 50:417.
54. Osada, T., Nagawa, H., Takahashi, T., Tsuno, N. H., Kitayama, J. and Shibata, Y. 2002. Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit highly efficient peptide-specific T-cell response. J. Immunother. 25:176.